📊

Executive Summary

Next-generation OX2R agonist with differentiated profile for neurological and neurodegenerative disorders

ORX142

OX2R · OX2R agonist
Phase 1 Wholly-owned

Target: OX2R

Full NameOrexin Receptor 2
PathwayOrexin/Hypocretin signaling

Mechanism of Action

TypeSelective OX2R agonist (small molecule)
DescriptionHighly potent and selective OX2R agonist with a pharmacological profile differentiated from ORX750, optimized for neurological indications
Indications: Neurological and neurodegenerative disorders

Target Biology

Same OX2R target as ORX750, but ORX142 is designed with a differentiated pharmacological profile optimized for neurological and neurodegenerative conditions where cognitive function, neuroprotection, and sustained wakefulness may be key therapeutic goals.

Clinical Data

No clinical trial data available.

Market Opportunity

Catalysts & Upcoming Events

EventTimingImportanceKey Metrics to WatchConsensus
Patient study initiationQ1 2026highWhich neurological indication is selected for patient studies
Patient study initiation for neurological disordersQ1 2026high
Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy